Antitumor effect of a small-molecule inhibitor of KRAS^G12D in xenograft models of mucinous appendicular neoplasms.

ABSTRACT: Pseudomyxoma peritonei (PMP) is a rare disease characterized by a massive accumulation of mucus in the peritoneal cavity. The only effective treatment is aggressive surgery, aimed at removing all visible tumors. However, a high percentage of patients relapse, with subsequent progression and death. Recently, there has been an increase in therapies that target mutated oncogenic proteins. In this sense, KRAS has been reported to be highly mutated in PMP, with KRAS^G12D being the most common subtype. Here, we tested the efficacy of a small-molecule KRAS^G12D inhibitor, MRTX1133, in a high-grade PMP xenograft mouse model carrying a KRAS^G12D mutation. The results obtained in this work showed a profound inhibition of tumor growth, which was associated with a reducti

SUBMITTER: Vazquez-Borrego MC 

PROVIDER: S-EPMC10704766 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature